RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
RedHill Biopharma (RDHL) Tops Q1 EPS by 29c, Revenues Miss
May 27, 2021 7:03 AM EDTRedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.05), $0.29 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $22.7 million.
Dror Ben-Asher, RedHill's Chief Executive Officer, said: "The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19... More
